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Aim of the database: Asthma is the most prevalent chronic disease in children, adolescents, 
and young adults. In Denmark (with a population of 5.6 million citizens), .400,000 persons 
are prescribed antiasthmatic medication annually. However, undiagnosed cases, dubious diag-
noses, and poor asthma management are probably common. The Danish National Database for 
Asthma (DNDA) was established in 2015. The aim of the DNDA was to collect the data on 
all patients treated for asthma in Denmark and to monitor asthma occurrence, the quality of 
diagnosis, and management.
Study population: Persons above the age of 6 years, with a specific focus on 6–44 years, are 
included. The DNDA links three existing nationwide registries of administrative records in the 
Danish health care system: the National Patient Register, the National Health Insurance Ser-
vices Register, and the National Prescription Registry. For each year, the inclusion criteria are a 
second purchase of asthma prescription medicine within a 2-year period (National Prescription 
Registry) or a diagnosis of asthma (National Patient Register). Patients with chronic obstructive 
pulmonary disease are excluded, but smokers are not excluded.
Descriptive data: A total of 366,471 prevalent patients with asthma have been identified (year 
2014 – as a preliminary test search). This number is in agreement with the estimates of ∼400,000 
inhabitants that are available for patients with possible asthma in Denmark. Data encompass the 
following quality indicators: annual asthma control visits and pharmacological therapy.
Main variables: The variables included are spirometry, as well as tools for diagnosis (including allergy 
testing), smoking status, height, weight, and acute hospital admissions and unscheduled visits.
Conclusion: DNDA is available from January 1, 2016.
Keywords: indicator, asthma control, asthma management, prescription data, hospital data
Aim of the database
Asthma is the most prevalent chronic disease in children, adolescents, and young 
adults living in western societies.1 In Denmark, according to the prescription data, 
the prevalence of asthma is .400,000, with an estimated 30,000 new diagnoses per 
year. However, these figures are questionable, as population studies indicate that sub-
stantially more patients have asthma, but also those persons without asthma are incor-
rectly treated with antiasthma medication. A gold standard diagnostic test for asthma 
is lacking, although in a specialist setting most asthma cases will be characterized by 
respiratory symptoms and a positive asthma challenge, whereas primary care often 
diagnoses asthma based on the symptoms only.2–4
The survival rates of treated Danish patients with lung cancer are presently the 
lowest among the Nordic countries. Therefore, one of the first established Danish 
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databases was the lung cancer database. This database was 
established with the primary task to implement the updated 
national guidelines and, furthermore, to secure the valid 
registration of clinical baseline data and quality parameters 
with the aim of significantly improving the quality of lung 
cancer surgery.5 The effects of this database have been clini-
cally relevant, and follow-up studies have shown an improved 
clinical practice and core results, reduced mortality, and 
reduced regional differences.6,7 Furthermore, patients suf-
fering from chronic obstructive pulmonary diseases (COPD) 
have been included in a Danish database, with the primary 
focus on hospital-based COPD management,8 and they have 
showed an increased quality of care in hospital setting. This 
is different from an asthma database, which aims to include 
all patients suffering from asthma.
These data illustrate the need of better quality in the 
care of the patients with a chronic illness. The occurrence of 
respiratory symptoms and signs of reversible airway obstruc-
tion characterize asthma. Nevertheless, not all patients with 
respiratory symptoms, such as wheezing, exercise-induced 
shortness of breath, or cough, should be diagnosed with 
asthma.9 Also a single spirometry is not sufficient to make a 
correct asthma diagnosis, which preferably should be based 
on a thorough history of respiratory symptoms and docu-
mentation of airway obstruction variability.10
In Denmark, most of the prescriptions of antiasthmatic 
drugs are made in primary care by general practitioners 
(GPs). However, large numbers of asthma in- and outpatients 
are treated in tertiary specialist care, ie, secondary care at 
hospital departments of pulmonology, internal medicine, 
and pediatrics. This makes it difficult to assess the overall 
quality of asthma management. To solve this, and in order to 
establish more accurate monitoring of asthma in the Danish 
population, in 2015 it was decided to establish a nationwide 
database of asthma cases in Denmark.
The Danish National Database for Asthma (DNDA) pro-
vides a tool to continuously collect and monitor the valid and 
complete data on the occurrence of asthma in Denmark for 
the quality of diagnosis and treatment and provide a resource 
for future epidemiological research in the area of asthma. 
This database is expected to significantly contribute to the 
improvement of asthma care in Denmark and, thus, places 
Denmark on the international forefront of asthma care.
Study population
The health care system in Denmark is almost universal and gen-
erally free of charge, covering all citizens. Since establishment 
of the Danish Civil Registration System (CRS)11 in 1968, all 
citizens of Denmark have a unique personal identification 
number (CPR number). All medical, social, and other admini-
strative public records use this unique number to identify 
citizens; thus, this number allows accurate linkage between 
registers. The database is based on the existing administrative 
nationwide records in the Danish health care system and will 
be maintained by the Danish Clinical Registries (RKKP). This 
database includes all patients with asthma who were diagnosed, 
monitored, or treated for the disease anywhere.
The DNDA links three existing nationwide registries 
of administrative records in the Danish health care system, 
namely, the National Patient Register (NPR),12 the National 
Health Insurance Services Register (NHISR),13 and the 
National Prescription Registry (NPrR).14
•	 The coverage of the NPR database Version 10 (The Inter-
national Classification of Diseases [ICD]-10) is ∼100% 
as reporting is compulsory and linked to the allocation 
of resources.
•	 The NHISR contains information on all services provided 
by GPs and specialist practitioners in Denmark. The aim 
of this register is to administrate reimbursement, thus 
providing precise service provision, but no information on 
patient diagnoses or test results. Procedure codes for the 
conduction of spirometry with and without reversibility 
test and skin prick test for allergy are available within 
this registry.
•	 The NPrR contains information on all prescriptions 
dispensed at Danish pharmacies. Each record contains 
among others the CPR number of the individual filling 
the prescription, as well as date, specific anatomical thera-
peutic chemical codes of the type of drug, and amount in 
dosage numbers.
For each year, the inclusion criteria for the DNDA were 
as follows:
1. All patients older than 6 years were included; however, 
due to an overlap between the symptoms of asthma and 
COPD specific, this review focuses on the age group 
between 6 years and 44 years, at which COPD is very 
uncommon. Furthermore, the age group ,6 years has 
difficulties in performing lung function, and the pattern 
of symptoms may reflect other diseases than asthma.
2. Second purchase of a prescription drug against asthma 
(anatomical therapeutic chemical codes R03) within a 
2-year period.
3. A hospital record as outpatient, inpatient, or emergency 
room patient that is coded with either ICD-10 J45 or 
J46 (asthma) as primary diagnosis or J45 or J46 as 
secondary diagnosis in combination with JXX (any 
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 respiratory  disease) or R06 (abnormalities in breathing) 
as  primary diagnosis. All patients with records coded 
with J44 (COPD) as primary or secondary diagnosis were 
excluded. However, patients with asthma who smoke were 
not excluded, and only those who have developed COPD 
were excluded, as the treatment of this disease and its lung 
pathology differ from asthma. Individuals were classified 
as having asthma with a date of inclusion equal to the 
earliest dates recorded in the NPR or the NPrR. We also 
use Civil Registration System to obtain information on the 
date of death or emigration of the patients (Figure 1).
4. In the future, the patients suffering both asthma and 
COPD, namely, asthma and COPD overlap syndrome, 
might be included due to participation in both databases.
Patients’ contacts with a GP were defined using the 
NHISR and claim codes relevant for spirometry and allergy 
tests.
Descriptive data
A total of 366,471 prevalent patients with asthma have been 
identified in the year 2014, and similar findings are expected 
during the following years of data collection.
Main variables
The indicators selected
We expect the final database to be available in 2017, with 
the primary aim of increasing asthma management among 
children and adults. Data variables will be available for 
research purposes and will be presented annually in a report 
issued by the Competency Centre for Clinical Epidemiology 
and Biostatistics East (KCEB-OE).
The data encompass monitoring the trends in the follow-
ing quality indicators: first, conduction of annual asthma 
control visits, pharmacological treatment, forced expira-
tory volume in 1 second, forced vital capacity, and asthma 
challenge testing; second, tools used for diagnosis in new 
cases and the proportion of skin prick tests performed or 
measurement of specific immunoglobulin E concentrations 
in new patients; and third, annual assessment of smoking 
status, height and weight measurements, and the proportion 
of patients with acute hospital treatment (Table 1).
Follow-up
Periodic assessments of the quality indicators were car-
ried out and published on a monthly basis in the regional 
Is the patient aged
6–44 years?
Does the patient
have a primary ICD-10 diagnosis:
J45 or J46 in
National Patient Register?
Has the patient purchased
at least two prescriptions of asthma
inhalation medicine registered in the
National Prescription Register
with ATC-code R03
within the last 2 years?
Does the patient
have a secondary ICD-10 diagnosis: J45 or J46
in combination with a primary ICD-10 diagnosis
for any respiratory disease JXX
or abnormalities in breathing R06 in
National Patient Register?
Does the patient
have a primary or secondary diagnosis for chronic obstructive
pulmonary disease with ICD-10 code J44 in
National Patient Register?
Prevalent study population
included in the
Danish National Database for Asthma
No
Yes
Yes
Yes
Yes
No
No
No Exclusion
Exclusion
Exclusion
No
Yes
Yes
Figure 1 Study population.
Notes: Study population includes all patients older than 6 years, with a specific focus on the group between 6 years and 44 years. Patients younger than 6 years have 
difficulties in performing the tests and have a broad pattern of nonasthma respiratory symptoms, and patients older than 44 years might have COPD and not asthma.
Abbreviations: ATC, anatomical therapeutic chemical; COPD, chronic obstructive pulmonary disease; ICD-10,  International Cassification of Disease Version 10.
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information systems, where the clinical units (hospitals, 
hospital departments, and GPs or specialized practitioners 
within a specified region) access their own results. All 
units ensure real-time registration and make use of their 
own results for further development and quality assurance 
in the units.
In the future, the database aims to include asthma diag-
nosis codes and clinical data (forced expiratory volume in 
1  second, forced vital capacity, height, weight, and  smoking 
status) registered by GPs and specialized practitioners. A com-
puter software, called Sentinel data capture (http://www.
dak-e.dk/flx/en/general-practice/sentinel-data-capture/), 
is designed to collect these key data as they are entered into 
the GPs’ and specialist practitioners’ electronic health record 
systems. The centralization and access to data collected by 
Sentinel in regard to patients with asthma is presently being 
revised.
Potential research
Although the database is still under establishment, the poten-
tial for research into asthma treatment and control is large, 
including, but not restricted to, geographic and age-related 
differences in diagnostic tests performed, therapy prescribed, 
therapy used, health care use, comorbidity, control of visit 
prevalence, and referral patterns, as well as changes in 
 variable incidences and prevalences over time.
Table 1 Description of the included indicator variables for the Danish National Database for Asthma
Area monitored Research question Included variablesa
Patient care is the patient monitored annually? % of patients with at least one primary/secondary care visit  
for asthma controlb
Pharmacological  
inhalation treatment
Does the patient’s treatment  
match the asthma control?
% of patients purchasing asthma inhalation medicine from the  
group of SABA alone at levels equivalent to .600 doses per  
year, with no usage of iCS at the same timec
is the patient receiving the  
correct treatment?
% of patients purchasing asthma inhalation medicine from the  
group of LABA or LAMA or LABA/LAMA in combination,  
with no usage of iCS at the same timec
Lung function tests is lung function tested annually? % of patients asked to perform FEv1 and FvC lung 
functionality tests at least once yearly among patients with 
known asthmab
is lung function tested when  
diagnosing new patients?
% of patients asked to perform FEv1 and FvC lung 
functionality tests in a period from 3 months before till 
3 months after first purchase of antiasthmatic prescription 
medication in a 2-year period or among patients with a new 
NPR asthma diagnosisd,e
Diagnostic tools Are the correct diagnostic tools  
used among new patients?
% of patients asked to perform PEF, variability, reversibility, 
or challenge test among the newly diagnosed asthma patients 
and patients who purchase the first antiasthmatic prescription 
medication in a 2-year periodd,e
Allergy is allergic response assessed in  
newly diagnosed patients?
% of patients who have been tested for allergy as either total 
allergic-specific IgE test or SPT among the newly diagnosed 
patients with asthma and patients who purchase the first 
antiasthmatic prescription medication in a 2-year periodd
Smoking status is smoking status recorded? % of patients who have been questioned regarding smoking 
and passive smoking and passive status at least once yearly 
among patients with known asthmab,f,g
Growth retardation is the patient’s weight and height  
registered annually?
% of patients who have had weight and height measured at 
least once yearly among patients with known asthmab,h
Acute hospital  
inpatient
Has the patient had emergency  
hospital contacts?
% of patients who had at least one acute hospital inpatient 
(,24 hours in duration) visit due to respiratory exacerbations 
in the year in question among patients with known asthmab
Notes: ain all instances, patient’s age, sex, date of diagnosis, and primary/secondary care institutions will be available. bBased on the total prevalent population. cBased on the 
population included according to the second purchase of asthma inhalation treatment medicine registered in the National Prescription Registry. dBased on the total incident 
population. eResults of lung function values extracted only from National Patient Registry will also be included in the National Registry for Asthma. fSmoking variables included 
present smoker, number of cigarettes per day for present smokers, ever smokers, never smokers, and patients exposed to passive smoke in home (living with a smoker) or 
workplace (working in a workplace in which smoking is permitted and at least one colleague smokes). gData on smoking status only available via National Patient Registry, as 
the registration of patient smoking by family physicians is not available. hResults of height and weight measurements extracted only from National Patient Registry will also 
be included in the National Registry for Asthma.
Abbreviations: FEv1, forced expiratory volume in 1 second; FvC, forced vital capacity; iCS, inhalation corticosteroid; igE, immunoglobulin E; LABA, long-acting β2-agonist; 
LAMA, long-acting muscarinic receptor antagonist; NPR, National Patient Register; PEF, peak expiratory flow; SABA, short-acting β2-agonist; SPT, skin prick test.
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More specific research areas included were as follows:
•	 Phase IV pharmaceutical real life trials.
Follow-up studies aimed at the evaluation of the long-
term effects of the rearrangement on the Danish health care 
infrastructure (centralization of smaller hospitals to super 
hospitals). The database plays an important role in research 
describing the trends in asthma care in Denmark, including:
•	 Patient trajectories monitoring in the health care system 
and the evaluation of why some patients are treated in 
primary care and others by specialists.
•	 Factors governing specialist treatment that could provide 
guidelines for the improvement of specialist treatment 
selection.
•	 The influence of comorbidities via linkage to other 
nationwide Danish health registers.
•	 The assessment of asthma care quality and patient 
response as a result of transfer of young patients with 
asthma from pediatric treatment to adult care. Investiga-
tion of long-term trends in asthma and lung function 
among incorrectly treated patients with asthma.
Strengths and limitations
The main strength of DNDA is that it centralizes impor-
tant data pertinent for asthma from three almost complete 
databases covering the entire Danish population. This cen-
tralization provides a potential for quality assessment and 
research that has never previously been available in one 
single database.
The main limitation of the database is that, in a given 
year, patients with asthma in Denmark who do not fulfill the 
database’s criteria are not included. However, these criteria 
are necessary for the database to primarily include patients 
for whom the asthma management requirements are fair 
(Table 1). This is also the reason why patients with asthma 
and COPD overlap syndrome are not included in the database. 
The restrictions are based on the pharmacoepidemiological 
 studies.15 This overlap between the two obstructive diseases 
might change in the future, as treatment modalities, such as 
the new biological drugs to the eosinophilic cells and the 
cytokines involved, can be used, independent of asthma or 
COPD and possibly also the overlap between the two diseases. 
This overlap will be solved in the future, and at present, all 
pharmaceutical studies are directed toward either asthma or 
COPD.
Another important issue is the lack of studies validating 
the asthma diagnosis codes in NPR, however, the database’s 
additional data on tools that are used to diagnose asthma 
improve the validity of these records. Furthermore, validation 
studies on NPR diagnosis codes for other diseases, such as 
COPD, have proven a very high standard.12,16
Conclusion
DNDA is available from January 1, 2016.
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